First Bight Ventures✓

Bio-based chemicals don't win by matching petroleum's price. They win when the plant sits next to the feedstock and skips the freight, the middlemen and the port bottlenecks baked into the oil model. That's the real cost curve.

Primient's iPROOF confirms what we underwrite every day: the valley of death isn't a science gap, it's a manufacturing gap. Fowler's point stands: technical risk, cost validation and investor fatigue hit together at scale, not separately.

Bio-isoprene only matters if it clears the same price floor as petroleum isoprene. Visolis hit that bar with Zeon on synthetic rubber, which is why the deal is a market signal, not a sustainability story.

The U.S. Treasury Department on Thursday proposed to expand existing outbound investment restrictions out of national security concerns, in a move set to further decouple venture capital ties between the U.S. and China. The proposed regulation widens the scope to prohibit Americans from investing in certain areas of semiconductor and microelectronics technologies such as high-bandwidth memory chips, as well as all AI systems (or SI systems in the White House’s lingo) in several countries including China, Russia, North Korea, Venezuela, and Cuba. The existing rule only prohibits American investments in AI systems that use computing power above a certain threshold, and doesn’t strictly prohibit investments in AI applications or AI systems developed for robotics. The proposed rule, which is open to public commentary until December 7, also seeks to restrict transactions in hypersonic systems and biotech, two sectors that aren’t covered by the existing rule that took effect in early 2025. Treasury said the proposed rule was based on direction from Congress in the Comprehensive Outbound Investment Security Act, passed as part of the Fiscal Year 2026 National Defense Authorization Act. By Jing YangSource: The Information

Rare earth separation has run on the same toxic solvent extraction since the 1960s. Alta Resource Technologies is using proteins to do the separation instead, aimed squarely at China's monopoly on refining. This is the Material Revolution applied to mining waste, not just biomass. Via C&EN.

ORNL just told the industry the quiet part: bioindustrial scale-up is not a biology problem, it is a manufacturing systems problem. Its new BioMADE membership bets on robotics, materials science and process engineering, not another strain improvement. That is the bottleneck we underwrite.

We’re swallowing microplastics. What happens inside us? New research suggests these particles can generate reactive radicals in water, raising fresh questions about potential health risks. #PFAS #Microplastics #Health

CANCER SHOULDN’T BE PART OF THE JOB. The EU is tightening workplace limits on cancer-causing chemicals. But what if we redesigned production, not just exposure limits? Biomanufacturing could replace some hazardous chemistry with bio-based processes. #Biobased #Chemicals #EU

AI’S BOOM. FOREVER CHEMICALS’ COMEBACK. Greenpeace warns AI data centers are fueling new demand for PFAS, including in cooling systems. The future of AI shouldn’t leave a toxic legacy. Innovation must mean safer materials, too. #PFAS #Foreverchemicals #AI #Datacenters

Bio-based plastics hit a new milestone! Sumitomo Chemical’s bio-based LCP reaches production scale, matching conventional LCP quality. Customer samples are next as the company prepares for mass production. #Plastics #Chemicals #Sustainability

RUSSIA’S NEXT BIG BET: BIOTECH Russia has approved a bioeconomy strategy through 2050, targeting new fuels, medicines and materials. AI and tech parks are part of the plan. #Bioeconomy #Russia #AI

Biomanufacturing can help build a safer chemical future. As chemical-security threats evolve, the response requires stronger detection, global cooperation and smarter production. Biomanufacturing can reduce reliance on hazardous feedstocks and fragile chemical supply chains by producing valuable materials through biological processes, with safety and security built in from the start. The opportunity is to pair INTERPOL’s call for cross-border chemical security with innovation that makes supply chains more resilient, traceable and sustainable. #Globalsecurity #Supplychain #Chemicals

Bio-Based Is Not a Silver Bullet for Chemical Decarbonization Feedstock limits, cost pressures, infrastructure gaps, and questions around scalability are forcing the industry to look beyond the hype and focus on what can truly deliver emissions reductions at scale. The future is not just bio-based. It is practical, measurable, and built for real-world adoption. #Decarbonization #Sustainability #CircularEconomy

Bio-Based Chemicals Are Not Automatically Green. Here’s the Reality Check. The race to decarbonize chemicals is accelerating, but “bio-based” does not guarantee lower emissions, stronger economics, or scalable impact. The real question is not whether a material comes from biomass. It is how it is made, what energy powers production, and whether the route can compete at commercial scale. #Biobased #Chemicals #Decarbonization #Sustainability

Europe’s chemical supply chains are under pressure to prove what is in every input, where it came from, and whether it meets stringent EU requirements. Biomanufacturing can be part of the answer. By producing specialty ingredients through more traceable, locally scalable biological processes, companies can reduce dependence on opaque supply networks and build compliance into sourcing from day one. The next advantage in European chemicals may not come from sourcing harder. It may come from making smarter. #EU #Supplychain #Chemicals

America’s biotech edge is moving faster than Washington. The next breakthrough in medicine, food, defense, and manufacturing may already be in the lab. But biotech leaders warn that outdated U.S. policy could turn innovation into a competitive vulnerability, especially as global rivals race to build their own advantage. The question is no longer whether biotech will reshape the economy. It is whether the U.S. will write the rules, or fall behind them. #Biotech #USA #Supplychain #Innovation

National labs keep confirming what the capital markets already priced in The bottleneck in bioindustrial manufacturing was never the science, it was scale-up capacity. #California #Biology #Scale